Previous 10 | Next 10 |
Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy™ (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies - Zokinvy increases survival by 2.5 years in children and young adults with Progeria ...
Gainers: [[NGA]] +6.6%. [[SRT]] +4.2%. [[EEX]] +3.7%. [[CLNE]] +3%. [[WPRT]] +2.6%.Losers: [[EIGR]] -10.3%. [[IHT]] -4.1%. [[IMKTA]] -3.5%. [[DNK]] -2.7%. [[ETM]] -2.3%. For further details see: CLNE, WPRT, EIGR and ETM among after-hours movers
Eiger Announces Positive Peginterferon Lambda - Lonafarnib Combination End of Study Results from Phase 2 LIFT HDV Study in Late-Breaker Session at The Liver Meeting Digital Experience™ 2020 - Week 48 (24 Weeks Post-Treatment) Results Presented - 23% of Patients BLOQ o...
Eiger Announces Case Studies Demonstrating Regression of Liver Fibrosis Following 48 Weeks of Therapy with Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection Presented at The Liver Meeting Digital Experience™ 2020 PR Newswire PALO ALTO...
Eiger Bio to Participate in November 2020 Investor Conferences PR Newswire PALO ALTO, Calif., Nov. 11, 2020 PALO ALTO, Calif. , Nov. 11, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization o...
Eiger BioPharmaceuticals (EIGR): Q3 GAAP EPS of -$0.52 beats by $0.07.Cash, cash equivalents, and short-term investments of $125.3M.Press Release For further details see: Eiger BioPharmaceuticals EPS beats by $0.07
Eiger BioPharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update PR Newswire PALO ALTO, Calif., Nov. 5, 2020 PALO ALTO, Calif. , Nov. 5, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the d...
Eiger Announces Abstracts Highlighting Peginterferon Lambda and Lonafarnib in Chronic Hepatitis Delta Virus (HDV) Infection Accepted for Presentation at The Liver Meeting Digital Experience™ 2020 PR Newswire PALO ALTO, Calif., Nov. 2, 2020 PALO ALTO, Calif. ...
On October 15, Eiger announced results of a Toronto General Hospital investigator-sponsored study in outpatients with mild to moderate COVID-19. As was seen with the Regeneron data for its monoclonal antibody cocktail, patients with a high baseline viral load demonstrated a statistica...
Gainers: [[FSI]] +24.2%. [[AMRN]] +3.8%. [[CHWY]] +3.8%. [[EIGR]] +3.7%. [[AFI]] +3.6%.Losers: [[KC]] -8.9%. [[MRTN]] -7.9%. [[NTN]] -6.6%. [[SOS]] -5.5%. [[RLGY]] -4%. For further details see: AMRN, CHWY, RLGY and KC among after-hours movers
News, Short Squeeze, Breakout and More Instantly...
Eiger BioPharmaceuticals Inc. Company Name:
EIGR Stock Symbol:
NASDAQ Market:
Eiger BioPharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today ...